H. Lundbeck A/S (HLUBF)

3,9100 -0,2500 (-6,01%) Al cierre: 03:56PM EDT

H. Lundbeck A/S

Ottiliavej 9
Valby 2500
Denmark
45 36 30 13 11
https://www.lundbeck.com

Sector(es): Healthcare
Sector: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 5681

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Charl van Zyl	President & CEO	5,34M	N/A	1967
Mr. Joerg Hornstein	CFO & Executive VP of Corporate Functions	1,23M	N/A	1977
Mr. Lars Bang	Executive Vice President of Product Development & Supply	1,14M	N/A	1962
Dr. Per Johan Luthman	Executive Vice President of Research & Development	1,27M	N/A	1959
Dr. Tarek Samad Ph.D.	Senior VP & Head of Research	N/A	N/A	N/A
Mr. Palle Holm Olesen	Chief Specialist & VP of Investor Relations	N/A	N/A	N/A
Ms. Tine Ostergaard Hansen	Senior Vice President of Corporate Communications & Public Affairs	N/A	N/A	1975
Ms. Dianne Holto	Executive Vice President of People & Organization	N/A	N/A	1973
Mr. Ole Chrintz	Senior Vice President of International Markets	N/A	N/A	1958
Dr. Rupert Sandbrink M.D., Ph.D.	Senior VP & Head of Clinical Development	N/A	N/A	1964

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.

Gobierno corporativo

El ISS Governance QualityScore de H. Lundbeck A/S, a día 1 de mayo de 2024, es 3. Las puntuaciones base son Auditoría: 4; Tablero: 5; Derechos de los accionistas: 9; Compensación: 1.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.